Riociguat-Discontinue Effects on Right HEART in CTEPH (RED-HEART)

Phase 3

Recruiting

• Conditions: Chronic Thromboembolic Pulmonary Hypertension
• Interventions: Drug: Riociguat; Drug: Routine Treatment

• Registration Number: NCT06922240
• Lead Sponsor: Suqiao Yang

Brief Summary

Riociguat and balloon pulmonary angioplasty (BPA) are established standard-of-care interventions for inoperable chronic thromboembolic pulmonary hypertension (CTEPH) with comparable evidence levels. However, the optimal combined treatment strategy remains unclear. Specifically, there is no consensus on whether riociguat should be continued long-term after achieving hemodynamic stability with BPA. Additionally, the long-term effects of riociguat discontinuation on right ventricular (RV) structure and function remain poorly characterized, particularly due to the lack of comprehensive noninvasive evaluations integrating cardiac magnetic resonance (CMR) and echocardiography. This prospective study aims to determine the hemodynamic impact of riociguat discontinuation in inoperable CTEPH patients who have achieved BPA treatment endpoints using right heart catheterization (RHC). Evaluate RV remodeling and functional changes after riociguat cessation through multimodal noninvasive imaging (CMR, echocardiography). Assess safety outcomes and identify potential rebound pulmonary hypertension or decompensated RV dysfunction associated with riociguat withdrawal.

Detailed Description

Not available

Study Timeline

• Study Start: 2025-03-21
• Study First Submitted: 2025-03-23
• Status Verified: 2025-04
• Study First Submitted QC: 2025-04-09
• Study First Posted: 2025-04-10
• Last Update Submitted: 2025-04-27
• Last Update Posted: 2025-04-30
• Primary Completion: 2026-10-30
• Study Completion: 2027-10-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 68

Inclusion Criteria

• Age ≥18 years old
• CTEPH was diagnosed and one of the following three factors was met: Pulmonary endarterectomy was technically impossible; Pulmonary endarterectomy is technically feasible, but the risk-benefit ratio is poor; Residual/recurrent pulmonary hypertension after pulmonary endarterectomy
• Subjects had been treated with BPA and had received a stable dose of riociguat for ≥12 weeks
• mPAP < 30mmHg
• Male subjects and female subjects of reproductive age are required to use effective contraception for at least 28 days after signing the informed consent form. Male subjects are not allowed to donate sperm and female subjects are not allowed to breastfeed.
• Subjects voluntarily sign written informed consent

Exclusion Criteria

• Severe hepatic and renal insufficiency (Child-Pugh Grade C/creatinine clearance < 30ml/min·1.73m²)
• The presence of severe infectious disease or severe bleeding tendency
• Combined with pulmonary hypertension of other types than CTEPH
• Other pulmonary hypertension targeting drugs are being used
• The expected survival time with cancer or other diseases is less than 6 months
• Pregnancy, lactation
• Subjects are currently participating in an interventional clinical trial
• In the investigator's judgment, a subject's medical abnormality, physical condition, or medical history may affect his or her ability to participate in or complete the study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
riociguat group	Riociguat	The subject was given comprehensive treatment in accordance with the guidelines and oral riociguat.
routine treatment group	Routine Treatment	The subject was given comprehensive treatment in accordance with the guidelines.

Primary Outcome Measures

Name	Time	Method
Change from Baseline in the Cardiac Output at 6 Months.	Baseline and 6-month follow-up	Cardiac Output was measured by right heart catheterization.

Secondary Outcome Measures

Name	Time	Method
Change from Baseline in the Pulmonary Vascular Resistance at 6 Months.	Baseline and 6-month follow-up	Pulmonary Vascular Resistance was measured by right heart catheterization.
Change from Baseline in the concentration of NT-proBNP at 6 Months.	Baseline and 6-month follow-up	The concentration of NTproBNP in serum was detected in pg/ml
Change from Baseline in the 6-minute walking distance at 6 Months.	Baseline, 3-month follow-up, and 6-month follow-up	6-minute walking distance was measured by 6-minute walking test
All-cause mortality	From the baseline to the completion follow-up,an average of 6 months	Observe and record All-cause mortality
Combined incidence of all-cause death, re-hospitalization or disability/incapacity events due to clinical exacerbation of pulmonary hypertension	From the baseline to the completion follow-up,an average of 6 months	Observe and record All-cause mortality, clinical exacerbation of pulmonary hypertension leading to re-hospitalization or disability/incapacity

Trial Locations

Locations (3)

China-Japan Friendship Hospital; 🇨🇳 Beijing, China

Beijing Anzhen Hospital; 🇨🇳 Beijing, China

Beijing Chao-Yang Hospital; 🇨🇳 Beijing, China